Find a Trial

Advancing investigational treatment options for people living with cancer.

Cancer

Solid Tumors - RTX-240

Rubius Therapeutics® is enrolling adults with relapsed/refractory or locally advanced solid tumor cancers into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-240. There are two Phase 1 arms enrolling adult patients with advanced solid tumor cancers – one to evaluate RTX-240 as monotherapy and the other to evaluate RTX-240 in combination with KEYTRUDA® (pembrolizumab)1.

LEARN MORE ABOUT THE RTX-240 CLINICAL TRIAL

Solid Tumors - RTX-224

Rubius Therapeutics is enrolling adults with relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, urothelial (bladder) cancer, head and neck cancer and triple-negative breast cancer, into a Phase 1/2 clinical trial to evaluate an investigational potential treatment option, called RTX-224. Refractory refers to patients who have received treatment, but the disease does not go into remission. Some patients experience remission and then a return of the disease, which is referred to as relapsed.

LEARN MORE ABOUT THE RTX-224 CLINICAL TRIAL

References:

  1. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


Thank you

We will contact you about your submission